Pharmaceutical compositions for the prevention and treatment of atherosclerosis and restenosis after PTCA
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Dec 18, 2007
Grant Date -
Apr 22, 2004
app pub date -
Nov 6, 2003
filing date -
Aug 24, 1998
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The present invention provides a pharmaceutical composition for the prevention or treatment of angiostenosis, comprising a compound inhibiting the function of midkine (MK) in blood vessel tissues as an effective ingredient. The present invention is useful for the prevention or treatment of angiostenosis attributed to arteriosclerosis or restenosis after percutaneous transluminal coronary angioplasty (PTCA). As compounds inhibiting the function of MK, antisense oligonucleotides that bind to a segment of a single-stranded mRNA transcribed from the MK gene to inhibit the synthesis of MK protein in cells, antibodies against the MK protein, and such can be used.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully